Celcuity (NASDAQ:CELC) Announces Earnings Results

Celcuity (NASDAQ:CELC) posted its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28), Zacks reports.

Here are the key takeaways from Celcuity’s conference call:

• REVTORPYK was FDA-approved for HR-positive, HER2-negative advanced breast cancer without detected PIK3CA mutations, and both its doublet and triplet regimens received preferred Category 1 recommendations in the NCCN guidelines.
• In the PIK3CA-mutant VIKTORIA-1 cohort, gedatolisib-based regimens significantly improved median progression-free survival to approximately 11 months versus 5.6 months for alpelisib plus fulvestrant, while treatment discontinuation due to adverse events was lower for gedatolisib. Celcuity plans to submit an sNDA in the third quarter of 2026.
• Celcuity remains confident that commercial shipments will begin in late Q3 2026. The company has completed its commercial infrastructure, deployed 88 oncology sales specialists, begun an expanded-access program, and estimates a U.S. addressable market exceeding $6 billion annually.
• The VIKTORIA-2 first-line breast cancer program has been expanded to include endocrine-sensitive patients, potentially broadening gedatolisib’s use across most newly diagnosed advanced HR-positive, HER2-negative patients. Celcuity also expects to provide additional prostate cancer data in Q4 2026.
• Second-quarter net loss widened to $78.9 million from $45.3 million year over year, while selling, general and administrative expenses rose sharply due to launch preparation. The company ended June with $754 million in cash and investments and expects funding into 2029, helped by a $575 million convertible-note offering.

Celcuity Trading Down 2.8%

NASDAQ CELC opened at $77.38 on Wednesday. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04. The firm has a 50-day moving average price of $88.21 and a 200 day moving average price of $103.65. The stock has a market capitalization of $3.79 billion, a P/E ratio of -18.00 and a beta of 0.19. Celcuity has a 52-week low of $44.42 and a 52-week high of $151.02.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $155.00 target price on shares of Celcuity in a report on Friday, August 14th. Guggenheim increased their target price on Celcuity from $165.00 to $175.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. JPMorgan Chase & Co. began coverage on Celcuity in a report on Thursday, September 17th. They set an “overweight” rating and a $157.00 target price for the company. Leerink Partners set a $155.00 target price on shares of Celcuity in a report on Tuesday, June 2nd. Finally, Stifel Nicolaus reduced their price target on Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Celcuity has a consensus rating of “Moderate Buy” and a consensus target price of $154.75.

Celcuity Company Profile

Celcuity, Inc is a biotechnology company focused on advancing personalized medicine through functional diagnostics. Its technology is designed to analyze living tumor cells obtained from patient tissue and identify abnormal signaling activity that may influence how a cancer responds to specific therapies.

The company’s primary platform, CELsignia, uses proprietary assays to measure the activity of cellular signaling pathways in a patient’s tumor cells. Celcuity develops these tests for use in oncology drug development, patient selection, and potentially as companion diagnostics to help identify patients who are most likely to benefit from targeted treatments.

Celcuity works with biopharmaceutical companies and research organizations to evaluate drug-response biomarkers and support precision oncology programs.